Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-622 in Mild to Moderate Asthma
NCT07330778Phase 1Recruiting
- Sponsor
- Celldex Therapeutics
- Start
- Jun 2026
- Primary completion
- Mar 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CDX-622 in asthma, sponsored by Celldex Therapeutics. Primary endpoint: Safety and tolerability profile at 12 weeks. Started Jun 2026; status: recruiting.
02
Drugs
CDX-622
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07330778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07330778.